July 09, 2026

In the United States, Men May Be More Likely Than Women to Receive Later-Stage Diagnoses for Many Cancer Types

Between 2015 and 2022, men were more likely than women to be diagnosed with regional and/or distant stages of 20 nonreproductive solid cancer types in the United States.

The ASCO Post

July 09, 2026

In the United States, Men May Be More Likely Than Women to Receive Later-Stage Diagnoses for Many Cancer Types

Between 2015 and 2022, men were more likely than women to be diagnosed with regional and/or distant stages of 20 nonreproductive solid cancer types in the United States.

The ASCO Post

July 08, 2026

Surgical Manual from Roswell Park Created to Advance Bladder Cancer Surgery Worldwide

Roswell Park Comprehensive Cancer Center announces the release of a new operative surgical manual authored by Khurshid Guru, MD.

Roswell Park Comprehensive Cancer Center

July 07, 2026

Baptist Health Cancer Care to Present Research on Precision Radiation Therapy Across Complex Cancers at ASTRO 2026

Experts across Baptist Health Herbert Wertheim Cancer Institute and Eugene M. & Christine E. Lynn Cancer Institute will present new radiation oncology research and clinical expertise at the 2026 Annual Meeting of the American Society for Radiation Oncology (ASTRO), September 26-30, 2026, in Boston.

Baptist Health South Florida

July 06, 2026

Dana-Farber Research Supports FDA Approval of New Therapy for “Double-Positive” Metastatic Breast Cancer

The U.S. Food and Drug Administration (FDA) has approved a new therapy regimen for patients with “double-positive” metastatic breast cancer based on results of the phase 3 PATINA study led by Otto Metzger, MD, Associate Medical Director of International Strategic Initiatives at Dana-Farber Cancer Institute.

Dana-Farber

July 06, 2026

Second Primary Malignancies After T-Cell–Engaging Bispecific Antibody Therapy

In a meta-analysis reported in JAMA Oncology, Tomasik et al found that second primary malignant neoplasms were a “clinically relevant complication” of treatment with T-cell–engaging bispecific antibod...

The ASCO Post

July 06, 2026

Second Primary Malignancies After T-Cell–Engaging Bispecific Antibody Therapy

In a meta-analysis reported in JAMA Oncology, Tomasik et al found that second primary malignant neoplasms were a “clinically relevant complication” of treatment with T-cell–engaging bispecific antibod...

The ASCO Post

July 02, 2026

2026 ASCO Kidney Cancer Highlights

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates

Dana-Farber

July 02, 2026

2026 ASCO Bladder Cancer Highlights

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the bladder cancer clinical updates

Dana-Farber

July 02, 2026

2026 ASCO Prostate Cancer Highlights

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates.

Dana-Farber